Jean-Louis Dasseux, Ph.D., M.B.A.
Founder and CEO, Cerenis Therapeutics
Dr. Jean-Louis Dasseux is the founder of Cerenis and one of the world’s leading experts in lipid metabolism, lipid-protein interaction, and cardiovascular disease. He has more than 25 years of experience in the pharmaceutical industry. Dr. Dasseux has generated more than 60 patents related to HDL, RLT, and the treatment of cardiovascular disease. He is the inventor of a high-capacity reverse lipid transport peptide HDL mimetic (ETC-642) and a series of small molecule compounds that raise HDL levels (ETC-1001 and ETC-1002). He held the positions of Senior Vice-President of Business Development and Technologies and Vice-President of Chemistry and Technologies at Esperion Therapeutics, which developed the first generation of HDL mimetics (pro-apoA-I, apoA-IMilano, and apoA-I peptide) until its acquisition by Pfizer for USD 1.3 billion. Before joining Esperion, he was Director of Research for French pharmaceutical company Fournier, where he established and managed its research center in Heidelberg, Germany. Jean-Louis Dasseux holds an M.B.A. from the Ross School of Business of the University of Michigan, in the United States. He obtained his Master's in biochemistry at the University of Bordeaux II and his Ph.D. in physical chemistry at the University of Bordeaux I. He has held postdoctoral positions at the Department of Chemistry of the University of Laval in Quebec, the Department of Physics at the University of Tennessee in Knoxville, Tennessee, and the European Molecular Biology Laboratory in Heidelberg, Germany.
Cyrille Tupin, C.P.A.
Chief Financial Officer
Mr. Tupin was previously Audit Director of Sygnatures, the largest private audit and consulting company in Toulouse, France. He spent more than seven years at PriceWaterhouseCoopers with 2 years of international experience in Canada. He has worked on a number of high-profile business transactions, including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French C.P.A. since 2002.
Renée Benghozi, M.D.
Chief Medical Officer
Dr. Renée Benghozi is an international clinical specialist who has over 30 years of experience in the clinical development of molecules in the cardiovascular and diabetes fields. She is a cardiologist and graduate of the Université Paris XII. Since earning her degrees, she has been practicing cardiology at the Henri Mondor Hospital (Créteil) and simultaneously in 1982 began a career in the pharmaceutical industry (Sanofi and Novartis) She has spent more than fifteen years at F. Hoffmann-La Roche Ltd. where she was recently International Medical Director. Her past career in clinical medicine and her substantial experience in the pharmaceutical industry with cardiology patients are also extremely valuable regarding her critical management role in drug development at Cerenis.
Constance Keyserling, M.S.
Sr. Vice President, Clinical Development
Ms. Keyserling has over 25 years of global clinical development experience at Parke-Davis, Pfizer, Esperion, and QuatRx. She was previously Vice President of Development Operations at QuatRx. Prior to that, Ms. Keyserling was Senior Director of Operations at Esperion, where her responsibilities included clinical program design and management, clinical outsourcing, regulatory operations and SOP systems development. Constance Keyserling holds a Master's degree in biostatistics from Harvard University.
Ronald Barbaras, Ph.D.
Director of Exploratory Biology
With a PhD in biochemistry, Ronald Barbaras has over 30 years of experience in lipid metabolism, the interactions between HDL and cardiovascular disease, including the binding of lipoproteins and the synthesis of cholesterol. Ronald Barbaras was formerly Research Director and group leader for ATP synthase, HDL metabolism and immune modulation at the National Institute of Health and Medical Research (INSERM), the French public research organization dedicated to biological, medical and public health. He was at the origin of the discovery of the F1-ATPase and P2Y13 receptor in the liver as key regulators of HDL elimination by the liver. He has published over 45 papers in international peer-reviewed journals.